Compare TZOO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TZOO | ACET |
|---|---|---|
| Founded | 1998 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 83.3M |
| IPO Year | 2003 | 2017 |
| Metric | TZOO | ACET |
|---|---|---|
| Price | $6.25 | $9.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $17.50 | ★ $48.33 |
| AVG Volume (30 Days) | 47.4K | ★ 80.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | $204.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $0.46 |
| 52 Week High | $12.39 | $9.84 |
| Indicator | TZOO | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 22.51 | 57.58 |
| Support Level | $5.45 | $7.45 |
| Resistance Level | $7.31 | $9.59 |
| Average True Range (ATR) | 0.21 | 0.53 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 0.94 | 73.95 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).